Search

Your search keyword '"Malyszko, Jolanta"' showing total 888 results
Start Over Author "Malyszko, Jolanta"
888 results on '"Malyszko, Jolanta"'

306. Perfusion defects on real-time myocardial contrast echocardiography predict higher mortality in patients with end-stage renal disease – A 3-year follow-up

Author

Tomaszuk-Kazberuk, Anna, primary, Sobkowicz, Bozena, additional, Malyszko, Jolanta, additional, Malyszko, Jacek S., additional, Kalinowski, Marek, additional, Sawicki, Robert, additional, Dobrzycki, Slawomir, additional, Mysliwiec, Michal, additional, and Musial, Wlodzimierz J., additional

Published
2010
Full Text
View/download PDF

325. Application of Myocardial Contrast Echocardiography for the Perfusion Assessment in Patients with End-Stage Renal Failure – Comparison with Coronary Angiography

Author

Sobkowicz, Bozena, primary, Tomaszuk-Kazberuk, Anna, additional, Kralisz, Pawel, additional, Malyszko, Jolanta, additional, Kalinowski, Marek, additional, Hryszko, Tomasz, additional, Malyszko, Jacek, additional, Dobrzycki, Slawomir, additional, and Musial, Wlodzimierz J., additional

Published
2008
Full Text
View/download PDF

327. 134

Author

Malyszko, Jolanta, primary, Malyszko, Jacek S., additional, Kozminski, Piotr, additional, Wanic-Kossowska, Maria, additional, Glowinska, Irena, additional, Ratajewski, Wlodzimierz, additional, and Iaina, Adrian, additional

Published
2007
Full Text
View/download PDF

330. Chronic kidney disease in patients with significant left main coronary artery disease qualified for coronary artery bypass graft operation.

Author

Zalewska-Adamiec, Malgorzata, Bachorzewska-Gajewska, Hanna, Malyszko, Jolanta, Malyszko, Jacek S., Kralisz, Pawel, Tomaszuk-Kazberuk, Anna, Hirnle, Tomasz, and Dobrzycki, Slawomir

Subjects
CHRONIC kidney failure, GLOMERULAR filtration rate, CORONARY artery bypass, DISEASE prevalence, DISEASE complications
Abstract

The article discusses a study which examines the prevalence of chronic kidney disease in patients with left main disease (LMD). The patients were divided into two groups according to estimated glomerular filtration rate (eGFR) and observed the progress after coronary artery bypass graft (CABG) treatment and complications. Findings reveal the prevalence of chronic kidney disease in patients with LMD treated with CABG.

Published
2015
Full Text
View/download PDF

337. Potassium management with finerenone: Practical aspects

Author

Wanner, Christoph, Fioretto, Paola, Kovesdy, Csaba P., Malyszko, Jolanta, Pecoits‐Filho, Roberto, Schnell, Oliver, and Rossignol, Patrick

Abstract

Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favourable effects on cardiorenal outcomes in patients with mild‐to‐severe chronic kidney disease with increased albuminuria and type 2 diabetes. Two large, randomized trials have evaluated the effects of finerenone on clinical outcomes. The first trial (FIDELIO‐DKD) investigated renal outcomes, and the second (FIGARO‐DKD) cardiovascular outcomes. Patients in the two studies had a high intrinsic risk of hyperkalemia due to type 2 diabetes, treatment with optimized doses of an inhibitor of the renin‐angiotensin system, and, in some patients, their advanced chronic kidney disease. This was reflected in the incidence of hyperkalemia in the placebo group during the trials. Patients on finerenone had a significantly higher incidence of hyperkalemia compared with patients on placebo, but treatment discontinuation due to hyperkalemia was low, and no patients experienced death attributable to hyperkalemia. Structured routine potassium monitoring with temporary treatment interruption and dose reduction, as used in the two trials, should ensure the safe use of finerenone to protect the kidneys and cardiovascular system of patients with albuminuric chronic kidney disease and type 2 diabetes. The aim of this document is to highlight the routine potassium management required when using finerenone and to provide practical recommendations. Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with mild to severe chronic kidney disease with increased albuminuria and type 2 diabetes. This article highlights the routine potassium management required when using finerenone and provides furthermore practical recommendations.

Published
2022
Full Text
View/download PDF

340. Renal anaemia treatment in haemodialysis patients in the Central and Eastern European countries in everyday clinical practice follow-up.

Author

Malyszko, Jolanta, Drozdz, Maciej, Zolkiewicz, Agnieszka, and Rutkowski, Boleslaw

Abstract

Background: Chronic kidney disease is almost always accompanied by anaemia. Erythropoietin-stimulating agents (ESA) can increase haemoglobin concentration and thus reduce the frequency of anaemia-related complications including the cardiovascular events. Aim: The aim of the study was to collect prospective data on 12-month standard ESA therapy used in haemodialyzed patients in selected CEE countries as well as on cardiovascular complications, iron status and anaemia treatment. Patients and methods: Fifty centres in 3 countries participated in the study. A group of 398 haemodialysed stable patients (M-231, F-167) aged 19-90 years (57.5 ± 14.7) on standard ESA therapy for chronic renal anaemia were recruited. Twelve-month prospective data on iron parameters, ESA therapy and cardiovascular events were collected. The use of iron, folic acid and blood transfusions were also assessed. Patient were divided into three groups according to ESA therapy start: group A-patients who received ESA after start of haemodialysis, group B-patients who received ESA within 3 months from the day of first haemodialysis and group C-patients who had received ESA more than 3 months before haemodialysis. Chi test for qualitative data and Kruskall-Wallis test for quantitative data with p < 0.05 were used in statistical analysis. Results: At prestudy period, the mean weekly dose of ESA in group C was statistically lower than in the remaining two groups (3,823 ± 3,169 vs. 5,276 ± 2,915 and 6,427 ± 3,441 units/week, p < 0.001), but during prospective phase of the study the doses did not differ among groups A, B and C. No major fluctuation of ESA administration schedule was observed during the study in the groups; however, at majority of visits, the mean frequency of ESA administration in group C was statistically higher than in groups A and B. At baseline visit, the haemoglobin concentration in group A patients (10.86 ± 1.34 g/dL) was slightly lower than in group B (11.26 ± 1.43 g/dL) and group C (10.98 ± 1.35 g/dL) ( p = 0.025), but at subsequent visits these differences disappeared and mean haemoglobin concentration was stable around 11 g/dL. Ferritin concentration increased from 280 ± 241 at baseline to 506 ± 405 at month 12, and no important differences in the groups were observed. The other haematological parameters (haematocrit, iron concentration) remained stable during the entire study. The frequency of blood transfusion and total volume of blood in group C were lower than in groups A and B. During the prospective 12-month follow-up, 23 (5.8 %) of the patients died and 35 (8.8 %) were transplanted. No differences in death or transplantation rate were observed among groups A, B and C. The number of patients with adverse events, serious adverse events or drug-related adverse events in all groups was similar. In conclusion, ESA therapy increased haemoglobin concentration and no major differences in haematological parameters among the groups were observed during the entire study irrespective of early versus late start. Mortality, cardiovascular events or other adverse events were similar among the groups during the observation period; however, the limitation of the study is the sample size. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results